美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

美國抗疫概念

1,836.02

-11.7391-0.64%

漲家數：- -

跌家數：- -

平家數：- -

市盈率：- -

高：1,843.55

開：1,843.55

低：1,812.56

收：1,847.72

成交量：3,542.32萬

成交額：20.78億

市值：1.49萬億

流通市值：1.46萬億

資料載入中...

總覽新聞資訊

DESTINY-Lung04 III期臨床研究顯示，優赫得®一線治療HER2突變晚期非小細胞肺癌患者的中位無進展生存期達14.3個月

生存期幾乎翻倍！BioNTech(BNTX.US)肺癌候選藥PRESERVE-003後期試驗告捷，腫瘤學轉型再獲關鍵支撐

生存期幾乎翻倍！BioNTech(BNTX.US)肺癌候選藥PRESERVE-003後期試驗告捷，腫瘤學轉型再獲關鍵支撐

Mabion與諾瓦瓦克斯達成合作，為其早期管線項目提供分析服務

Mabion與諾瓦瓦克斯醫藥簽署第12號工作聲明，深化現有生產協議下的合作

強生骨科業務引阿波羅興趣，潛在200億美元交易推動盤前股價上漲1.2%

強生Rybrevant聯合化療在EGFR外顯子20插入突變非小細胞肺癌中實現迄今報告最長的中位總生存期

強生：RYBREVANT聯合化療在EGFR外顯子20插入突變非小細胞肺癌中實現已報告的最長中位總生存期。

阿斯利康的乳腺癌藥物晚期臨床試驗失敗

Moderna Inc(MRNA)股票9月11日盤中上漲8.63%：關鍵驅動因素揭曉

TradingKey中文

源達研究報告：全A盈利加速上行，科技與資源景氣引領

雷克蘭醫療工業第二季度銷售額達5010萬美元，略低於市場預期5140萬美元

投洽會「金鑰匙」再啓：雙向投資動能強勁，未來產業站上C位

安進（AMGN）聯合療法III期臨床達主要終點

美股盤後速遞：三大股指期貨集體下跌，SK海力士跌0.56%，英特爾跌0.44%；WTI原油期貨升逾1%；美軍稱摧毀伊朗革命衞隊5艘油輪

Assembly Biosciences有望獲得高達2.8億美元里程碑付款及美國境外特許權使用費

Assembly Biosciences旗下Gs-1179預計2026年底前將推進至生殖器皰疹二期臨床試驗階段

Assembly Biosciences：吉利德獨享HSV HPI項目臨床開發與商業化權利

Assembly Biosciences行使與吉利德關於HSV解旋酶-引物酶抑制劑項目的美國利潤分成選擇權

吉利德科學(GILD)股票9月8日盤中下跌3.26%：釋放什麼信號？

TradingKey中文

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/hant/stock/BK4568/news?page=2"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4568","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4568\",,,,,undefined,":{"symbol":"BK4568","market":"US","secType":"PLATE","nameCN":"美國抗疫概念","latestPrice":1835.9814,"timestamp":1789489818047,"preClose":1847.7206,"halted":0,"volume":35419611,"delay":0,"changeRate":-0.006353,"floatShares":0,"shares":0,"eps":0,"marketStatus":"交易中","change":-11.739136,"latestTime":"09-15 12:30:18 EDT","open":1843.5487,"high":1843.552,"low":1812.5594,"amount":2077645289.571023,"amplitude":0.016773,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1789502400000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":4.787725,"peRate":46.585694,"turnoverRate":0.002553,"increases":2,"decrements":17,"flats":0,"marketCap":1493484072755.5,"floatMarketCap":1459196240233.5},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4568\",,,,,undefined,":{"symbol":"BK4568","high":1843.552,"amplitude":0.016773,"preClose":1847.7206,"low":1812.5594,"pbRate":"4.787725","latestPrice":1836.0228,"volume":35423205,"delay":0,"open":1843.5487,"prevYearClose":1637.1339,"prevWeekClose":1829.725,"prevMonthClose":1860.7577,"prevQuarterClose":1731.2963,"fiveDayClose":1852.4125,"twentyDayClose":1778.7885,"sixtyDayClose":1624.1672,"secType":"PLATE","market":"US","turnoverRate":0.002553,"peRate":46.585694,"marketCap":1493531168563.5,"floatMarketCap":1459240751465.5,"timestamp":1789489821330,"nameCN":"美國抗疫概念"},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4568\",pageSize:20,pageCount:2,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2667645276","title":"DESTINY-Lung04 III期臨床研究顯示，優赫得®一線治療HER2突變晚期非小細胞肺癌患者的中位無進展生存期達14.3個月","url":"https://stock-news.laohu8.com/highlight/detail?id=2667645276","media":"美通社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667645276?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 19:16","pubTimestamp":1789384560,"startTime":"0","endTime":"0","summary":"德曲妥珠单抗组的中位PFS为14.3个月，而帕博利珠单抗联合化疗组为8.3个月。\" 阿斯利康全球执行副总裁、肿瘤研发负责人Susan Galbraith表示：\"DESTINY-Lung04是首项在HER2突变晚期NSCLC患者中，证实PFS优于全球一线标准治疗的III期临床研究。在DESTINY-Lung04临床研究中，德曲妥珠单抗的安全性特征与其已知安全谱总体一致，未发现新的安全性问题。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/5046853_ZH46853_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/5046853_ZH46853_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["IE00B19Z4B17.USD","LU0128525929.USD","DCO","LU0432979614.USD","LU2237443465.HKD","LU0566484027.USD","BK4231","IE00B66KJ199.SGD","LU2237443978.SGD","LU2237443895.HKD","ADC","NETL","BK4007","BK4187","CR","ORR","LU2456880835.USD","FXN","PFS","LU2089984988.USD","PXI","LU2236285917.USD","LU2462157665.USD","LU1829250122.USD","LU0708994859.HKD","LU1267930573.SGD","LU2237443622.USD","ROKT","BK4585","AZNH","BK4568","LU0289739699.SGD","BK4213","LU0058720904.USD","LU0320765992.SGD","LU1559883803.SGD","LU0109394709.USD","LU2417539215.USD","LU0310800379.SGD","BK4588","IE0031619046.USD","IE00B7SZL793.SGD","PR","BK4161","AZN","LU2237443549.SGD","IE00B3T34201.USD","BK4195","BK4211"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667570696","title":"生存期幾乎翻倍！BioNTech(BNTX.US)肺癌候選藥PRESERVE-003後期試驗告捷，腫瘤學轉型再獲關鍵支撐","url":"https://stock-news.laohu8.com/highlight/detail?id=2667570696","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667570696?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 18:26","pubTimestamp":1789381582,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4585","BK4588","BK4551","BK4535","CANC","BK4548","BNTX","BK4568","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667064657","title":"生存期幾乎翻倍！BioNTech(BNTX.US)肺癌候選藥PRESERVE-003後期試驗告捷，腫瘤學轉型再獲關鍵支撐","url":"https://stock-news.laohu8.com/highlight/detail?id=2667064657","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667064657?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 18:26","pubTimestamp":1789381582,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，BioNTech周一表示，一项后期临床试验显示，其候选药物gotistobart在一种特定类型肺癌中，较标准治疗带来具有临床意义的总生存期获益。公司称，该试验为PRESERVE-003 III期临床试验，纳入的是在接受既往免疫治疗和化疗后疾病仍出现进展的鳞状非小细胞肺癌患者;与标准治疗化疗相比，gotistobart使生存期几乎翻倍。鳞状非小细胞肺癌约占所有肺癌病例的25%至30%，在非小细胞肺癌中属于侵袭性较强的亚型。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495746.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BNTX","BK4551","BK4548","BK4585","CANC","BK4588","BK4139","BK4535","BK4568"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117895984","title":"Mabion與諾瓦瓦克斯達成合作，為其早期管線項目提供分析服務","url":"https://stock-news.laohu8.com/highlight/detail?id=1117895984","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1117895984?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 16:47","pubTimestamp":1789375656,"startTime":"0","endTime":"0","summary":"Mabion公司宣布，已与诺瓦瓦克斯医药达成一项合作协议。该协议涵盖分析服务的实施与提供，旨在支持诺瓦瓦克斯多个早期阶段管线项目的推进。此番合作意味着，Mabion将在诺瓦瓦克斯候选药物的研发进程中扮演关键角色，为其提供必要的分析技术支持。通过这一安排，两家公司将协同发力，助力早期研发工作顺利开展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVAX","BK4139","BK4588","BK4568","BK4547","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128143190","title":"Mabion與諾瓦瓦克斯醫藥簽署第12號工作聲明，深化現有生產協議下的合作","url":"https://stock-news.laohu8.com/highlight/detail?id=1128143190","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1128143190?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 16:47","pubTimestamp":1789375628,"startTime":"0","endTime":"0","summary":"Mabion公司宣布，已与诺瓦瓦克斯医药正式签署第12号工作声明。此举旨在现有制造协议框架内，进一步拓展双方的合作广度。这份新签署的文件，标志着两家企业协作关系的又一次深化推进。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4568","NVAX","BK4547","BK4139","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171745492","title":"強生骨科業務引阿波羅興趣，潛在200億美元交易推動盤前股價上漲1.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=1171745492","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1171745492?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 16:18","pubTimestamp":1789373891,"startTime":"0","endTime":"0","summary":"据报道，强生公司的骨科业务部门吸引了阿波罗全球管理的关注，这一潜在交易估值或达200亿美元。受此消息提振，强生股价在盘前交易中上涨了1.2%。知情人士透露，私募股权巨头阿波罗已就收购强生骨科业务的可能性进行了初步接触。强生骨科业务涵盖创伤修复、关节置换、脊柱外科及运动医学等多个细分领域，在全球范围内拥有广泛的市场布局。截至发稿时，强生和阿波罗均未对此传闻发表官方评论。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4533","BK4588","LU1551013342.USD","IE00BLSP4452.SGD","LU1066053197.SGD","IE00B775SV38.USD","LU1043141123.HKD","LU1914381329.SGD","BK4568","AAUM","LU2133065610.SGD","IE00BFTCPJ56.SGD","LU0345770308.USD","LU2592432038.USD","BMED","LU0069063385.USD","LU2750360997.AUD","LU0162691827.USD","IE0001KFT4U8.USD","LU2417539215.USD","LU2750360641.GBP","LU0795875169.SGD","LU1061106388.HKD","LU0106831901.USD","LU1674673428.USD","LU1244550221.USD","LU1228905037.USD","LU0787776722.HKD","LU1244550577.SGD","SG9999013999.USD","IE00BLSP4239.USD","IE00BVYPNV92.GBP","LU0234572021.USD","LU2236285917.USD","LU1430594728.SGD","SG9999001440.SGD","LBO","IE00B3PB1722.GBP","LU1221951129.SGD","IE000WAW04H5.SGD","LU1221951046.USD","LU1496350502.SGD","LU0122379950.USD","LU0210536198.USD","GPZ","BK4559","LU1059921491.USD","LU2213496289.HKD","LU1066051498.USD","LU0792757196.USD","IE00B19Z3B42.SGD","LU0889566641.SGD","FHLC","IE000F7OJYX1.SGD","LU0057025933.USD","LU1162221912.USD","LU2129689605.HKD","LU1718418525.SGD","IE0034235303.USD","LU0432979614.USD","LU0472753341.HKD","LU0114720955.EUR","IE00BFXG1179.USD","IE0000B7K699.USD","LU2430703095.HKD","LU0289961442.SGD","LU0289739699.SGD","LU2023250330.USD","IE000MB6IJN5.SGD","BK4550","IE00B3S45H60.SGD","BK4581","IE00BJT1NW94.SGD","LU2505996681.GBP","XLV","LU0683600562.USD","LU1057294990.SGD","LU1043141396.HKD","IE00BSNM7G36.USD","LU1506573853.SGD","LU2347655156.SGD","BK4135","LU0234570918.USD","LU1023059063.AUD","LU0511384066.AUD","IE00B19Z3581.USD","IHE","IE00B2B36J28.USD","LU2505996509.AUD","LU2602419157.SGD","LU0203347892.USD","LU1894683264.USD","LU1074936037.SGD","IE00B1BXHZ80.USD","IXJ","LU1066051811.HKD","LU1585245621.USD","LU1196500208.SGD","LU1267930813.SGD","LU0098860793.USD","JNJ","LU1280957306.USD","MEDX","SG9999001176.USD","LU0882574055.USD","LU1935042991.SGD","LU0466842654.USD","LU1791807156.HKD","LU1551013425.SGD","SG9999002224.SGD","LU1989771016.USD","IE00BBT3K403.USD","LU2129689431.USD","IE000M9KFDE8.USD","LU0070217475.USD","LU2129689514.USD","PRVT","LU0345770993.USD","LU2471134879.HKD","LU0289739343.SGD","LU0345769128.USD","LU0006061336.USD","LU0820561909.HKD","BK4585","LU1629891620.HKD","IE0002270589.USD","IE00BN8TJ469.HKD","LU0210528500.USD","LU0345769631.USD","LU1674673691.USD","BK4532","IE00B3T34201.USD","LU0124676726.USD","LU0820562030.AUD","LU0912757837.SGD","LU1778281490.HKD","APO","LU2487616109.SGD","SG9999002232.USD","LU2112291526.USD","LU2456880835.USD","BK4504","LU0964807845.USD","LU0689626769.HKD","IE00BZ1G4Q59.USD","LU2403377893.USD","LU2471134952.CNY","LU0689472784.USD","IE0009355771.USD","LU0203345920.USD","LU2471134796.USD","IE000SO60NU8.SGD","IE00BGHQF631.EUR","BK4184","LU1228905540.USD","LU1032955483.USD","LU0943347566.SGD","JDOC","PJP","LU1261432733.SGD","FTXH","LU0320765646.SGD","LU1732800096.USD","LU0426417589.USD","IE00B42XCP33.USD","LU1032466523.USD","IYH","LU2089984988.USD","SG9999001176.SGD","BK4592","IE00B4R5TH58.HKD","IE000BZT7R73.USD","LU0053666078.USD","LU0058720904.USD","IE00B7SZLL34.SGD","LU0994945656.USD","LU2471134523.USD","SGXZ57979304.SGD","LU2756315318.SGD","LU0640476718.USD","SGXZ80539844.SGD","RXL","LU1929549753.HKD","LU0545562505.USD","LU1894683348.USD","IE00BJJMRZ35.SGD","IE00BDGV0183.EUR","LU1066051225.USD","BK4007","LU0072461881.USD","LU0426412945.USD","LU2430703251.USD","TRUH","BK4534","LU1983299246.USD","LU2896262040.SGD","IE00BVYPNW00.USD","LU2430703178.SGD","LU1291159041.SGD","LU1732799900.SGD","LU1668664300.SGD","GDOC","LU1244550494.USD","IE0002141913.USD","LU0985320562.USD","LU1145028129.USD","LU0795875086.SGD","LU0820561818.USD","LU2468319806.SGD","VHT","LU1121112475.USD","LU2756315664.SGD","LU1323610961.USD","IE00BKVL7J92.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120093998","title":"強生Rybrevant聯合化療在EGFR外顯子20插入突變非小細胞肺癌中實現迄今報告最長的中位總生存期","url":"https://stock-news.laohu8.com/highlight/detail?id=1120093998","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1120093998?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 09:47","pubTimestamp":1789350464,"startTime":"0","endTime":"0","summary":"强生公司日前公布了一项重磅临床数据——其旗下药物Rybrevant与化疗联用，在携带EGFR外显子20插入突变的非小细胞肺癌患者中，取得了目前公开报告中最长的中位总生存期。EGFR外显子20插入突变，历来被视为治疗难点，可选方案有限且疗效欠佳。观察人士指出，这不仅能巩固Rybrevant在精准医疗版图中的地位，更可能重塑晚期非小细胞肺癌的一线治疗格局。强生能否借此在竞争激烈的肺癌药物市场中进一步扩大优势，值得持续跟踪。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B7SZLL34.SGD","IE00BZ1G4Q59.USD","LU0114720955.EUR","LU0426412945.USD","BK4581","LU1059921491.USD","LU1074936037.SGD","LU1066053197.SGD","LU2896262040.SGD","IE000MB6IJN5.SGD","LU0787776722.HKD","LU0820561818.USD","LU0320765646.SGD","LU2505996509.AUD","LU0289961442.SGD","LU0203347892.USD","IE000M9KFDE8.USD","LU1228905037.USD","LU2089984988.USD","LU2430703095.HKD","LU0795875169.SGD","LU1430594728.SGD","LU2430703178.SGD","LU0210536198.USD","LU0943347566.SGD","LU2417539215.USD","LU0053666078.USD","IE00BVYPNV92.GBP","LU1551013425.SGD","LU2129689431.USD","LU1674673428.USD","IE00BN8TJ469.HKD","IE00BSNM7G36.USD","LU1066051225.USD","SGXZ80539844.SGD","LU2430703251.USD","LU0124676726.USD","BK4559","LU1196500208.SGD","LU0426417589.USD","LU0795875086.SGD","LU1778281490.HKD","LU0070217475.USD","LU2505996681.GBP","LU2129689514.USD","LU1221951129.SGD","LU2602419157.SGD","SGXZ57979304.SGD","LU2487616109.SGD","IE0002270589.USD","IE00BFTCPJ56.SGD","LU2756315664.SGD","BK4585","LU1585245621.USD","LU2471134796.USD","JDOC","LU2347655156.SGD","IE0000B7K699.USD","IE00B4R5TH58.HKD","LU2750360641.GBP","TRUH","LU1244550221.USD","RXL","LU0162691827.USD","LU0820562030.AUD","LU1244550494.USD","LU0345770308.USD","LU1043141396.HKD","IE00BDGV0183.EUR","LU1894683264.USD","LU2023250330.USD","LU2592432038.USD","IE000F7OJYX1.SGD","LU1935042991.SGD","LU0889566641.SGD","BK4592","IE00B19Z3581.USD","IE00B2B36J28.USD","LU1629891620.HKD","LU0792757196.USD","IE0001KFT4U8.USD","LU1267930813.SGD","LU1914381329.SGD","IE00BGHQF631.EUR","BK4504","IE00BVYPNW00.USD","IE00BFXG1179.USD","LU1057294990.SGD","LU2133065610.SGD","SG9999013999.USD","LU0234570918.USD","LU1066051811.HKD","LU1983299246.USD","LU2213496289.HKD","LU1244550577.SGD","XLV","LU0985320562.USD","IE00BLSP4452.SGD","LU0432979614.USD","BK4588","BK4534","LU1732799900.SGD","IYH","LU1929549753.HKD","LU1023059063.AUD","IE0034235303.USD","IE0009355771.USD","LU1032955483.USD","LU1261432733.SGD","LU1718418525.SGD","IE00BJJMRZ35.SGD","LU0689472784.USD","LU1066051498.USD","LU0098860793.USD","LU1894683348.USD","IE000SO60NU8.SGD","BK4568","SG9999002224.SGD","LU1121112475.USD","JNJ","IE00B19Z3B42.SGD","LU1032466523.USD","BK4007","LU0234572021.USD","LU0994945656.USD","LU1732800096.USD","LU2403377893.USD","VHT","IE00B3T34201.USD","LU0345769128.USD","LU2756315318.SGD","SG9999001176.SGD","IE00B42XCP33.USD","LU2456880835.USD","IXJ","LU2471134523.USD","LU1043141123.HKD","BK4533","IE000WAW04H5.SGD","LU0057025933.USD","LU0820561909.HKD","LU2468319806.SGD","LU0203345920.USD","SG9999001176.USD","BMED","LU0345770993.USD","LU0964807845.USD","LU1280957306.USD","LU0058720904.USD","LU1674673691.USD","LU2236285917.USD","LU1506573853.SGD","LU2471134879.HKD","IE000BZT7R73.USD","LU0683600562.USD","LU1496350502.SGD","SG9999002232.USD","SG9999001440.SGD","LU1221951046.USD","PJP","IE00BKVL7J92.USD","LU1162221912.USD","LU0210528500.USD","IHE","LU2129689605.HKD","LU0345769631.USD","LU0289739699.SGD","LU0640476718.USD","BK4550","LU0069063385.USD","IE00B3PB1722.GBP","LU1551013342.USD","LU0882574055.USD","LU0466842654.USD","LU2750360997.AUD","IE00B1BXHZ80.USD","IE00BJT1NW94.SGD","LU1291159041.SGD","LU1989771016.USD","LU0689626769.HKD","LU0289739343.SGD","LU1061106388.HKD","LU1228905540.USD","LU0072461881.USD","FHLC","IE00BLSP4239.USD","LU2471134952.CNY","LU0912757837.SGD","GDOC","LU0511384066.AUD","FTXH","IE0002141913.USD","IE00BBT3K403.USD","LU0545562505.USD","MEDX","LU2112291526.USD","LU1145028129.USD","LU0472753341.HKD","BK4532","LU0122379950.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667631840","title":"強生：RYBREVANT聯合化療在EGFR外顯子20插入突變非小細胞肺癌中實現已報告的最長中位總生存期。","url":"https://stock-news.laohu8.com/highlight/detail?id=2667631840","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667631840?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 09:46","pubTimestamp":1789350398,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IE00BGHQF631.EUR","LU2471134523.USD","LU0053666078.USD","LU1145028129.USD","PJP","BK4588","FTXH","IE00BVYPNV92.GBP","LU2592432038.USD","GDOC","BK4568","IE0001KFT4U8.USD","BMED","LU0683600562.USD","VHT","IE0002141913.USD","LU2471134879.HKD","LU2133065610.SGD","LU0426417589.USD","LU0072461881.USD","IHE","BK4533","IE00B3T34201.USD","LU1280957306.USD","LU1674673691.USD","LU0820561909.HKD","IE00BLSP4239.USD","IYH","LU1032466523.USD","LU1935042991.SGD","MEDX","FHLC","IXJ","LU2430703095.HKD","TRUH","LU0511384066.AUD","LU1894683264.USD","XLV","JDOC","IE0000B7K699.USD","RXL","IE00BFTCPJ56.SGD","IE00BDGV0183.EUR","LU0985320562.USD","LU1244550494.USD","LU2089984988.USD","BK4550","LU0122379950.USD","BK4559","JNJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666574841","title":"阿斯利康的乳腺癌藥物晚期臨床試驗失敗","url":"https://stock-news.laohu8.com/highlight/detail?id=2666574841","media":"路透中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666574841?lang=zh_tw&edition=fundamental","pubTime":"2026-09-12 04:29","pubTimestamp":1789158581,"startTime":"0","endTime":"0","summary":"阿斯利康的乳腺癌药物晚期临床试验失败路透9月11日-阿斯利康（AstraZeneca）AZN.L周五表示，其一款乳腺癌药物在晚期临床试验中未能达到改善无进展生存期的主要目标。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260911:nL4T4531G8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AZNH","LU0320765992.SGD","LU2456880835.USD","LU0128525929.USD","LU2237443549.SGD","LU0109394709.USD","LU2237443978.SGD","BK4588","LU1829250122.USD","LU2237443382.USD","IE00B3T34201.USD","LU2468319806.SGD","LU2417539215.USD","LU0029864427.USD","LU0058720904.USD","LU2462157665.USD","AZN","BK4585","LU0432979614.USD","LU0889565916.HKD","BK4568","LU0708994859.HKD","LU2236285917.USD","LU2237443895.HKD","LU2237443622.USD","LU2237443465.HKD","LU0289739699.SGD","BK4007","LU1267930573.SGD","LU0310800379.SGD","LU2089984988.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666657657","title":"Moderna Inc(MRNA)股票9月11日盤中上漲8.63%：關鍵驅動因素揭曉","url":"https://stock-news.laohu8.com/highlight/detail?id=2666657657","media":"TradingKey中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666657657?lang=zh_tw&edition=fundamental","pubTime":"2026-09-12 01:16","pubTimestamp":1789146984,"startTime":"0","endTime":"0","summary":"• 受机构买盘重新涌入及盘整巩固的推动，莫德纳出现上行波动。\n• intismeran autogene 的 3 期临床试验结果验证了其肿瘤学平台。\n• 最新年度营收为 19.4 亿美元，净亏损为 28.2 亿美元。","market":"sg","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/zh-hans/news/market-movers/262164048-market-movers-mrna-20260911","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","BK4139","BK4534","BK4588","MRNY","BK4585","GNOM","BK4532","WDNA","BK4533","BK4548","MRNA","LGHT","IDNA","MRNX","BK4501","BK4551"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666231475","title":"源達研究報告：全A盈利加速上行，科技與資源景氣引領","url":"https://stock-news.laohu8.com/highlight/detail?id=2666231475","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666231475?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 17:59","pubTimestamp":1789120740,"startTime":"0","endTime":"0","summary":"来源：源达投资要点全A盈利加速上行，ROE稳步回升2026H1全A营收端延续扩张态势，利润增速进一步抬升。除科技与资源品主线外，景气修复多点扩散。科创板盈利绝对增速仍显著领先。图7：重点指数的营收累计同比增速图8：重点指数的归母累计同比增速资料来源：Wind，源达信息证券研究所资料来源：Wind，源达信息证券研究所1．4全A ROE维持上行，且回升斜率有所加快2026Q2全部A股扣非ROE较一季度继续上行，回升斜率有所加快。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-09-11/doc-inirnais6788401.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["APT","QTOC","GGII","BK4099","TTM","BK4123","159982","AIPO","BK4523","BK4568","399300","WISE","DRMY","DISK","EPAI","ARTY","CHAT","VTHR","BK4086","AGIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160476534","title":"雷克蘭醫療工業第二季度銷售額達5010萬美元，略低於市場預期5140萬美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1160476534","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1160476534?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 04:25","pubTimestamp":1788985534,"startTime":"0","endTime":"0","summary":"9月9日（路透社）——雷克兰医疗工业公司（Lakeland Industries）公布第二季度财报，数据显示其运营支出为2060万美元。值得注意的是，该公司本季度销售额达到5010万美元，而此前IBES综合预估值为5140万美元，实际业绩略逊于市场预期。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B7SZL793.SGD","IE0031619046.USD","IE00B66KJ199.SGD","BK4568","IE00B19Z4B17.USD","BK4202","LAKE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666533439","title":"投洽會「金鑰匙」再啓：雙向投資動能強勁，未來產業站上C位","url":"https://stock-news.laohu8.com/highlight/detail?id=2666533439","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666533439?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 20:38","pubTimestamp":1788957480,"startTime":"0","endTime":"0","summary":"9月8日至11日，第二十六届中国国际投资贸易洽谈会(以下简称“投洽会”)在厦门国际博览中心举行。本届大会以“扩大双向投资共促全球发展”为永久主题，围绕“投资中国”“中国投资”“国际投 ...","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20260909/c679754294.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20260909/c679754294.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["LU2237443382.USD","LU0289739699.SGD","AZN","LU2236285917.USD","BK4588","LU2456880835.USD","LU2417539215.USD","AZNH","LU0029864427.USD","LU0058720904.USD","LU2237443622.USD","LU0310800379.SGD","LU1829250122.USD","LU2237443978.SGD","LU2468319806.SGD","LU0708994859.HKD","BK4007","LU0128525929.USD","LU0432979614.USD","LU0320765992.SGD","LU2237443895.HKD","BK4585","IE00B3T34201.USD","LU0889565916.HKD","LU2462157665.USD","LU2237443549.SGD","LU2089984988.USD","BK4568","LU2237443465.HKD","LU1267930573.SGD","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666712586","title":"安進（AMGN）聯合療法III期臨床達主要終點","url":"https://stock-news.laohu8.com/highlight/detail?id=2666712586","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666712586?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 16:59","pubTimestamp":1788944360,"startTime":"0","endTime":"0","summary":"金吾财经 | 安进公布，双特异性T细胞衔接器Imdelltra联合阿斯利康PD-L1抑制剂英飞凡，在广泛期小细胞肺癌的后期临床试验中实现总生存期延长。这家加州生物制药企业披露III期DeLLphi-305研究中期数据，该试验达成广泛期小细胞肺癌患者总生存期主要终点。该项全球试验评估该组合作为一线维持治疗，受试者既往接受过包含英飞凡的治疗且病情未发生进展。研究同时达成无进展生存期、客观缓解率两项次要终点。","market":"nz","thumbnail":"https://static.szfiu.com/news/20210810/NjNkZWQ4NGZiN2I3MDYxNDlhOTlmZGM4ZTUwODkzNDUzNTE2.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/NjNkZWQ4NGZiN2I3MDYxNDlhOTlmZGM4ZTUwODkzNDUzNTE2.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"305840","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BJJMRZ35.SGD","AMGN","BK4566","LU0109394709.USD","LU2468319806.SGD","LU2237443978.SGD","LU2112291526.USD","LU2237443895.HKD","BK4581","BIB","AZNH","PJP","LU0889565916.HKD","IE0002141913.USD","LU0128525929.USD","LU0122379950.USD","IE00BFTCPJ56.SGD","LU2242652126.USD","BBH","IE00B4R5TH58.HKD","LU1571399168.USD","BK4533","LU1023059063.AUD","LU0058720904.USD","LU0868494617.USD","LU2456880835.USD","LU0708994859.HKD","IBBQ","LU2242646821.SGD","LU0289739699.SGD","LU0432979614.USD","LU1829250122.USD","IBB","LU2236285917.USD","IE00B2B36J28.USD","PBE","LU2237443622.USD","LU0029864427.USD","BK4139","BK4568","BK4534","BK4585","LU2237443382.USD","LU1267930573.SGD","LU2462157665.USD","LU2089984988.USD","TBXU","SG9999001440.SGD","AZN","BK4599"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666305095","title":"美股盤後速遞：三大股指期貨集體下跌，SK海力士跌0.56%，英特爾跌0.44%；WTI原油期貨升逾1%；美軍稱摧毀伊朗革命衞隊5艘油輪","url":"https://stock-news.laohu8.com/highlight/detail?id=2666305095","media":"中新经纬","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666305095?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 09:03","pubTimestamp":1788915814,"startTime":"0","endTime":"0","summary":"北京时间9月9日，美股盘后，三大股指期货小幅下跌，存储芯片概念股涨跌不一；WTI原油期货涨超1%；全球最大主权基金拟大幅减持美债。三大股指期货小幅下跌美股三大股指期货小幅下跌。截至发稿，道指期货跌0.06%，纳指期货跌0.11%，标普500指数期货跌0.06%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://stock.eastmoney.com/a/202609093868824457.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.eastmoney.com/a/202609093868824457.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2506952097.USD","TSLY","STSLAmain","MUG","LU1582986433.USD","07766","04335","LU2506951958.HKD","XDAT","IE00BMPRXQ63.HKD","LU2089283258.USD","LU2168564149.EUR","LU2458330169.SGD","LU0345768740.USD","LU2087621335.USD","LU0072461881.USD","LU0158827948.USD","LU0170899867.USD","SKHX","SGXZ31699556.SGD","LU1153585028.USD","LU1585245621.USD","LU2065170008.USD","BK4549","IE00BMPRXR70.SGD","LU2237957811.SGD","LU0052756011.USD","HBMX","INT","LU2430703178.SGD","LU1670711123.USD","RSPC","GB00B4QBRK32.GBP","BK4535","LU0198837287.USD","IE00B4JS1V06.HKD","NVDS.UK","IE0004086264.USD","LU1721428933.USD","LU0726765562.USD","IE000Q6AESB8.SGD","IE00B5TLWC47.USD","LU0203345920.USD","LU0708994859.HKD","SKHY","HK0000320264.USD","LU0444971666.USD","LU0552385451.USD","DRMY","HK0000819398.USD","LU2552382215.SGD","APLY","SG9999014906.USD","TSLT","LU0211328371.USD","LU1059921491.USD","CHPX","NVD","BK4511","LU0347712357.USD","LU2028103732.USD","IE00B19Z8X17.USD","DIPS","IE00BYXW3230.USD","LU1861558580.USD","LU2210150020.SGD","SPTE","LU1880398471.USD","LU1267930490.SGD","LU1951200564.SGD","LU0648000940.SGD","AGOX","LU1670627923.USD","LU2543165471.USD","METV","IE00BLSP4239.USD","LU0965509101.SGD","LU0029864427.USD","LU2552382132.HKD","LU0203347892.USD","LU1992135472.HKD","SNVD.UK","BK4515","LU0011850046.USD","LU0433182093.SGD","LU0128525929.USD","WATS","LU0106261372.USD","IE0000B7K699.USD","LU2168563687.JPY","CLIX","LU2023250843.SGD","IE00BN8TJ469.HKD","BK4512","LU0314106906.USD","LU0943347566.SGD","LU1564329461.SGD","LU2244417387.USD","LU2637965513.SGD","LU1267930573.SGD","IE000YTNTUN2.SGD","GOOY","LU1069344957.HKD","2NVD.UK","LU2413666699.HKD","SG9999002224.SGD","IE00BQXX3D17.EUR","HK0000304797.USD","LU1935043536.SGD","SMHX","LU1551013342.USD","LU1894683264.USD","ROM","LU1868836757.USD","IE00B775SV38.USD","LU1301847155.USD","IE0003U64NQ7.SGD","TSLL","NVDB","LU1623119135.USD","LU2381873111.SGD","LU1043141123.HKD","TSDD","TLA","LU0545562505.USD","LU2322448957.HKD","IE000KEQY171.SGD","USD","LU2089284900.SGD","XLK","LU0683600562.USD","LU2491050154.USD","LU0234570918.USD","LU1244550221.USD","AMZO","IE00BJTD4N35.SGD","LU1718418525.SGD","LU0823413587.USD","SG9999015978.USD","TSLA","LU1868836591.USD","MIC","FCOM","LU0553294199.USD","FDTX","LU0234572021.USD","GXPC","LU1236620834.HKD","NVD2.UK","IE000ITXATA3.USD","SKHYV","LU2097344357.USD","LU2237443978.SGD","LU0130103400.USD","LU2417539215.USD","SG9999015952.SGD","TYLG","LU1804176565.USD","LU1366192091.USD","LU1720051108.HKD","LU0251131958.USD","IE000W1ABFV2.USD","AZYY","LU0496365809.HKD","IE00B3SWFQ91.USD","LU0894485498.HKD","LU0545039389.USD","LU2237443622.USD","LU1956131251.USD","LU0312595415.SGD","IE00BFSS7M15.SGD","LU2458330243.SGD","SG9999014898.SGD","LU1803068623.USD","LU1127390331.HKD","LU2286300806.USD","IDNA","LU1697837992.HKD","AMZG","LU0289941410.SGD","TTXU","MRNX","FTEC","LU0251132253.USD","CMAG","NVDL","TDIV","LU0308772762.SGD","LU1732800096.USD","LU1066051811.HKD","LU2357627491.SGD","LU1989763005.USD","LU1221951129.SGD","LU0472753341.HKD","LU1642822529.SGD","LU2487616109.SGD","LU1645745479.HKD","LU1316542783.SGD","LU1989773731.SGD","LU2272731600.USD","MSFY","MULL","LU0321505439.SGD","LU1064131342.USD","LU2237438978.USD","LU0266013472.USD","NVDD","SG9999001424.SGD","AAPL","FBL","LU0345770308.USD","LU1074936037.SGD","LU0823397285.USD","LU2125154935.USD","LU0345768153.USD","BK4505","BK4533","LU0072462426.USD","LU1880398554.USD","BK4555","BK4097","LU1582987324.SGD","IE00B1BXHZ80.USD","NULC","NVC","SGXZ51526630.SGD","LU1430594728.SGD","LU1894683348.USD","LU1145028129.USD","LU0208291251.USD","LU0823411888.USD","TESL","LU2133065610.SGD","INYY","BK4585","LU0149725797.USD","IE00BDCRKT87.USD","LU0894486033.HKD","LU0130102774.USD","LU0820562030.AUD","LU1923622614.USD","LTL","IE00BLSP4452.SGD","LU0109392836.USD","LU1839511570.USD","LU0345774391.USD","BK4596","LU0390134368.USD","LU0353189680.USD","LU0879622024.SGD","LU2168564065.EUR","IE00BDRTCR15.USD","LU2506951875.HKD","LU0215105999.USD","LU0289960550.SGD","LU1400636491.USD","NVDQ","BK4501","SKHZ","LU2896262040.SGD","LU0143551892.USD","LU2999663052.SGD","LU1551013425.SGD","AAPW","LU0097036916.USD","MSFL","TSLZ","LU2023250330.USD","LU0130517989.USD","IE0002270589.USD","SG9999018857.SGD","GOOP","LU1235295455.SGD","LU0080751232.USD","LU1116320901.HKD","LU2092937221.SGD","LU2764263203.CNY","IE000WAW04H5.SGD","LU2404859741.USD","LU2092627202.USD","LU1035775433.USD","LU0203201768.USD","LU1236620750.USD","SG9999014567.USD","ESLG","LU0823434583.USD","LU2360032135.SGD","SGXZ99366536.SGD","NVD3.UK","IE00BZ1G4Q59.USD","SMETAmain","GB00BDT5M118.USD","LU2168564495.EUR","LU1815336760.USD","SK","LU2361044865.SGD","LU1069347547.HKD","BK4554","IE00B3M56506.USD","LU0210533765.USD","LU0395794307.EUR","IE0004091025.USD","LINT","07388","LU0985320562.USD","GGLL","BK4532","LU2461242641.AUD","OGIG","RULE","LU1670710661.SGD","LU2764263039.SGD","TSII","LU0211327993.USD","LU2271345857.HKD","LU3102509885.SGD","LU0354030438.USD","EFIV","INTW","LU1778281490.HKD","BK4567","LU2083900584.USD","LU2360106780.USD","BK4527","LU0061475181.USD","LU1267930730.SGD","LU0528227936.USD","AAPY","AIQ","BK4122","LU1989764664.SGD","LU2191332357.HKD","SAMZNmain","SGXZ81514606.USD","WDNA","BK4099","BAI","LU2265009873.SGD","LU0820561818.USD","LU2931357623.SGD","LU2168564222.USD","IE00BJTD4V19.USD","LU0048573561.USD","LU2326559502.SGD","LU2023251221.USD","BK4592","TSLG","LU1951198990.SGD","LU0823397103.USD","AMZW","IE00BFXG1179.USD","LU0211331839.USD","LU1032955483.USD","BK4548","LU0238689110.USD","LU2272731782.SGD","SMOG","EMSF","LU2456880835.USD","LU2602419157.SGD","TRFK","LU1242518857.USD","LU0889565833.HKD","LU1814569148.SGD","BK4516","LU1917777945.USD","IE00B19Z8W00.USD","07366","METG","MUYY","METQ","LU2403377893.USD","LU2125909759.SGD","BK4559","LU0965509010.AUD","LU0345769631.USD","LU0960925559.SGD","LU1043141396.HKD","IE00BYQQ9H92.USD","LU1244550577.SGD","BK4507","MSFW","LU2452424414.USD","BK4612","LU0107464264.USD","IE00BD6J9T35.USD","LU1037948897.HKD","BK4529","LU0942090050.USD","LU1196500208.SGD","LU1323610961.USD","LU0124676726.USD","LU1571399168.USD","LU1914381329.SGD","SG9999000418.SGD","LU1974910355.USD","LU0057025933.USD","AMZP","MSFD","LU0157215616.USD","LU0868494708.USD","LU0225283273.USD","CNEQ","IE00BJJMRY28.SGD","LU1261432733.SGD","LU2746668461.USD","LU0070302665.USD","LU2462591277.SGD","GGLS","LU2125909593.SGD","LU0061474960.USD","ILDR","LU0788109477.HKD","LU0823434740.USD","LU1934455863.HKD","LU2361045086.USD","LU2041044095.USD","IE00BKVL7J92.USD","LU0353189763.USD","LU0061474705.USD","NVDU","GNOM","LU2317271919.USD","LU2347655073.USD","LU1340139317.AUD","MSFX","LU0310800379.SGD","FTXL","LU2294711713.HKD","LU0823413660.USD","BK4588","IGV","LU0823414478.USD","LU1037948541.HKD","LU1868837136.USD","BK4581","LU1935042215.USD","SG9999001077.SGD","WUGI","LU2756315664.SGD","ABFL","SOXQ","SG9999015986.USD","LU2954938101.SGD","LU1119994496.HKD","LU0957808578.USD","LU1670710588.SGD","LU1670711040.USD","NVDY","IE0004445015.USD","LU0158827781.USD","LU0690374961.EUR","IE00B19Z3581.USD","SKHN","LU2471134952.CNY","AMZU","HK0000914660.USD","LU0689626769.HKD","LU2279689827.SGD","LU0949170772.SGD","LU2463028550.USD","BK4576","IE00BHPRN162.USD","RTH","LU0053666078.USD","LU2290526834.HKD","LU2065171311.SGD","TSLP","LU0069063385.USD","THMR","AMAA","LU0289961442.SGD","LU2430703095.HKD","LU2249611893.SGD","LU2097344431.USD","TSYY","JGRO","LU0274383776.USD","MRNA","NVDA","HK0000306685.HKD","LU0068578508.USD","BK4553","NVDS","LU2413666426.HKD","LU0949170426.SGD","LU0557290698.USD","LU2750360997.AUD","SG9999018865.SGD","IETC","LU0672654240.SGD","LU1821325948.USD","LU0708995401.HKD","LU0162691827.USD","AMZY","LU1815333072.USD","GOOX","IE0034235295.USD","BK4528","LU0786609619.USD","LU0203202063.USD","BK4561","LU0096364046.USD","LU0314104364.USD","LU0321505868.SGD","GOOW","LU1400636574.HKD","LFGY","LU1582986359.USD","LU2148611432.USD","LU1334329650.SGD","LU2247934214.USD","LU1206713676.USD","LU1988902786.USD","GB00B4LPDJ14.GBP","LU0994945656.USD","LU1803068979.SGD","LU2237443465.HKD","IE00BN29S564.USD","LU1228905540.USD","NVII","TSLS","SMU00main","LU0976567544.SGD","LU0792757196.USD","LU2322448791.USD","LU0950375773.USD","IE00BMPRXN33.USD","LU2102340556.USD","LU2491049909.HKD","MACW.SI","TSLW","LU2462591350.SGD","LU1035773651.USD","LU1699723380.USD","LU0784384876.USD","LU2211815571.USD","LU0256863902.USD","BK4141","IE0009356076.USD","NVYY","LU0878866978.SGD","LU2065171402.SGD","SG9999014559.SGD","LU1202635105.USD","LU0965508806.USD","BK4608","BK4543","IE00BZ199S13.USD","LU1989764748.USD","LU2125154778.USD","IE0009G5SDU7.USD","LU2097829019.USD","LU0174119429.USD","ARTY","LU1235294995.USD","LU2506951792.HKD","LU1923622291.USD","LU1852331112.SGD","IE00B4YYXB79.USD","IE000MB6IJN5.SGD","LU0964807845.USD","LU2125909916.SGD","LU0494093205.USD","LU2491050071.SGD","NVDX","LU2362540622.SGD","SG9999004303.SGD","LU2720916845.USD","IE00BK4W5L77.USD","LU0426417589.USD","LU0256863811.USD","LU0477156797.USD","LU1291159041.SGD","LU1992135399.USD","LU2111349929.HKD","LU0127658192.USD","LU1506573853.SGD","LU2756315318.SGD","LU2125909247.SGD","META","CRSH","MRNY","LU0823414551.USD","LU0289739343.SGD","LU1791710582.SGD","IE00BFSS8Q28.SGD","LU0323240290.USD","LU0265550946.USD","FBYY","LU1934455194.USD","LU0310799852.SGD","LU2357305700.SGD","LU0689472784.USD","LU1935042488.USD","LU2471134523.USD","IE00BJJMRX11.SGD","LU0276348264.USD","LU1003077747.HKD","LU1791710400.SGD","LU1868836914.USD","FBX","LU2242649171.HKD","AMZN","LU2210149790.SGD","LU2063271972.USD","LU2077746001.SGD","LU0133085943.USD","LU2357125470.USD","VGT","LU2361044949.HKD","LU2471134879.HKD","LU2108987350.USD","LU1066051225.USD","LU1280957306.USD","GOU","LU0466842654.USD","LU0859254822.USD","CGGO","CHAT","IE0034235188.USD","LU0154236417.USD","LU2237443382.USD","MSFT","QQQA","AIS","LU2552382058.USD","IXN","LU1861215975.USD","LU1232071149.USD","LU0138981039.USD","LU0251142724.SGD","LU1691799644.USD","IE00B7SZLL34.SGD","ONLN","IE00BJLML261.HKD","LU1883839398.USD","METU","SGXZ23171101.USD","IE00BQXX3C00.GBP","LU2860962120.EUR","AMZD","BK4614","SAAPLmain","LU0187121727.USD","LU0787776722.HKD","LU0820561909.HKD","LU0882574139.USD","TEK","LU1979441026.SGD","LU0128525689.USD","LU2505996509.AUD","IE00B7KXQ091.USD","LU0823421333.USD","XLC","XNTK","LU1181866309.USD","LGHT","IE00BSNM7G36.USD","LU2023250504.SGD","LEGR","IE00BFXG0V08.USD","LU2394011477.USD","MUU","SINTCmain","CQTM","LU1923623000.USD","SNVDAmain","LU0345769128.USD","LU1989772840.SGD","LU2087625088.SGD","WANT","LU1201861249.SGD","USAW.SI","3NVD.UK","VOX","BK4170","TSLQ","LU1564329115.USD","IE0004445239.USD","BK4568","LU2237443549.SGD","FDRV","LU2275660780.HKD","HK0000320223.HKD","WLDR","LU1303367103.USD","SKUU","LU2237443895.HKD","EGGY","LU0980610538.SGD","LU1116320737.USD","LU1066051498.USD","IE00BQXX3F31.USD","SOCL","LU0738911758.USD","LU0070217475.USD","GOOL","LU0417517546.SGD","SKHQ","TSLR","SMH","IE00BKDWB100.SGD","BK4504","HULL","FXL","LU1066053197.SGD","BK4538","GOOGL","LU1935043023.USD","LU1934455277.USD","09788","ELOL","LU1366333091.USD","LU1674673428.USD","LU2347655156.SGD","LU0081259029.USD","LU0211326839.USD","LU0210528500.USD","LU2430703251.USD","LU0354030511.USD","NVDW","HK0000914686.HKD","LU0006306889.USD","LU0784383803.USD","LU0795875169.SGD","LU2473716301.USD","LU0889566641.SGD","LU0175139822.USD","LU1206712785.SGD","LU2047632596.USD","SKHA","BK4077","LU0210536198.USD","AAPX","07788","LU0757359954.USD","LU1935043452.HKD","LU0130518102.USD","IOSX","09366","BK4573","LU2462157665.USD","IE00B5949003.HKD","IE00B3S45H60.SGD","BK4604","LU0171293334.USD","LU0985489474.SGD","IE000F7OJYX1.SGD","LU1868837300.USD","AMZZ","BK4571","LU0444973449.USD","LU1435385759.SGD","LU0661504455.SGD","LU1032466523.USD","LU0640476718.USD","LU0912757837.SGD","LU1144417596.USD","LU1496350171.SGD","BK4579","SG9999002232.USD","TSLO","LU1674673691.USD","LU0642271901.SGD","LU2100268510.USD","LU1989772923.USD","SG9999014575.USD","HK0000304805.HKD","SG9999015358.SGD","SG9999017495.SGD","SOXY","IE00BK4W5M84.HKD","LU0082616367.USD","LU2054465674.USD","LU2362541273.HKD","LU1267930813.SGD","LU1670756490.USD","LU0871640123.AUD","IE00B775H168.HKD","LU0868494617.USD","LU1242518931.SGD","IE00BKPKM429.USD","LU0342679015.USD","LU0345770993.USD","SGXZ44715902.SGD","IE00BBT3K403.USD","MSFO","BOBP","TSL","07709","LU0348723411.USD","GOGL","NVDG","LU0096362180.USD","LU0477156953.USD","LU1633808545.USD","LU1989771016.USD","ESUM","LU2750360641.GBP","LU2404859667.USD","FBY","LU0823417653.USD","LU1823568750.SGD","LU2098885051.SGD","LU2089985449.USD","LU0345774631.USD","IE00B19Z3B42.SGD","AAPB","SKHL","IE000SO60NU8.SGD","LU1121112475.USD","LU1712237335.SGD","SG9999015945.SGD","BK4605","LU1201861165.SGD","LU2213496289.HKD","SKYY","SG9999014914.USD","AIFD","MSFC","BK4503","USXF","LU1548497426.USD","METW","HYNX","TEST","ANV","LU1935042991.SGD","IE0001KFT4U8.USD","INTC","LU0690374615.EUR","LU1732799900.SGD","LU0426412945.USD","BK4139","BK4598","LU2433249047.HKD","LU1564329628.SGD","LU0323239441.USD","LU0648001328.SGD","SKDD","DISK","LU1670628061.USD","BK4602","SMSFTmain","AAPD","LU0077335932.USD","LU0965509283.SGD","LU1564329032.USD","SHOC","LU1267930227.SGD","HK0000532082.HKD","CHPS","LU0719512351.SGD","LU0957791311.USD","LU1084165304.USD","TESC","LU0861579265.USD","LU0079474960.USD","LU0456855351.SGD","LU2471134796.USD","LU1983260115.SGD","LU0211326755.USD","LU0476273544.USD","BK4566","SKHU","LU1046421795.USD","LU0320765059.SGD","LU0323591593.USD","BK4514","IE00B19Z9505.USD","LU2360108059.USD","IE00BFMHRM44.USD","AAPU","LU1244550494.USD","LU0048584097.USD","BK4550","09766","LU2250418816.HKD","WISE","MUZ","LU1228905037.USD","LU0310800965.SGD","LU0795875086.SGD","LU2065169927.USD","PTF","LU2272731865.HKD","SG9999014880.SGD","LU0267386448.USD","LU2764262908.HKD","PSI","LU0757359368.USD","LU1629891620.HKD","SG9999014542.SGD","LU0056508442.USD","DRIV","IE000BZT7R73.USD","MUD","LU0109391861.USD","BK4577","BK4587","BK4551","LU2362541513.USD","AIPI","LU0724617625.USD","BK4525","LU1221951046.USD","LU2092937148.SGD","LU2237957902.USD","LU2592432038.USD","SGXZ80539844.SGD","IE00BWXC8680.SGD","LU2505996681.GBP","LIT","LU0823421416.USD","LU2264538146.SGD","LU2298321311.HKD","LU2106854487.HKD","BK4220","LU0784385840.USD","FAI","IDRV","LU0742534661.SGD","LU2236285917.USD","NVIW.SI","IE0034235303.USD","NVDO","LU2211817866.USD","LU1861559042.SGD","LU1489326972.SGD","HK0000306701.USD","LU1188199696.SGD","LU0094547139.USD","METD","SG9999015341.SGD","LU1582987597.SGD","LU0979878070.USD","LU2506952170.USD","BK4534","SNPE","LU1861220033.SGD","LU0320765489.SGD","BK4574","TRUC","LU0302445910.USD","LU0316494557.USD","LU0823417737.USD","LU0511384066.AUD","LU1496350502.SGD","IE00B1XK9C88.USD","LU0784385170.HKD","SOXX","TSLI","BK4524","LU1861127337.USD","CLSE","GAMR","VT","BK4575","IE000M9KFDE8.USD","LU2095319765.USD","AAPE","LU1429558221.USD","MSFU","LU2242650005.HKD","LU1720051017.SGD","LU2420271590.USD","IE0005OL40V9.USD","LU2746668974.SGD","09388","LU0095938881.EUR","LU1400636657.SGD","LU2048586759.USD","LU0265550359.USD","MU","LU2360107168.USD","TTEQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136308873","title":"Assembly Biosciences有望獲得高達2.8億美元里程碑付款及美國境外特許權使用費","url":"https://stock-news.laohu8.com/highlight/detail?id=1136308873","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136308873?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 04:02","pubTimestamp":1788897732,"startTime":"0","endTime":"0","summary":"Assembly Biosciences公司日前披露，其在海外市场具备资格获取最高达2.8亿美元的里程碑款项，外加相应特许权使用费收入。据悉，这家生物科技企业所预期的资金流入将源自美国以外地区。对Assembly Biosciences而言，这笔潜在收入不仅反映其管线资产的外部合作价值，也可能为其后续研发投入提供坚实支撑。市场人士认为，此类非美国市场的收益结构有助于分散地域风险，增强公司财务韧性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIB","LU1934455194.USD","TMED","LU2087621335.USD","LU1430594728.SGD","LU1778281490.HKD","LU0882574055.USD","LU0965509101.SGD","BK4583","IE00BZ1G4Q59.USD","LU1037948897.HKD","TBXU","IE0002270589.USD","IE00B3T34201.USD","LU0861579265.USD","LU0114720955.EUR","BK4139","IBBQ","LU0823416689.USD","LU0965509010.AUD","LU1066051498.USD","LU2089984988.USD","LU2357627491.SGD","LU0889565916.HKD","LU1674673428.USD","LU0859254822.USD","LU0289739699.SGD","LU0965508806.USD","LU1061106388.HKD","LU1674673691.USD","LU1934455277.USD","LU1839511570.USD","LU1023059063.AUD","BK4585","LU1571399168.USD","BK4578","LU1934455863.HKD","IE00BSNM7G36.USD","LU2324357040.USD","IE00B19Z3B42.SGD","LU0965509283.SGD","IE00B19Z3581.USD","BK4532","IE00BKVL7J92.USD","BK4566","LU1037948541.HKD","SG9999015945.SGD","BBH","LU0320765992.SGD","LU2112291526.USD","BK4568","LU1066053197.SGD","IE00B7SZLL34.SGD","LU0234570918.USD","SG9999015986.USD","LU1057294990.SGD","LU1585245621.USD","LU2468319806.SGD","LU0058720904.USD","LU0122379950.USD","MEDI","BK4588","GILD","BMED","BK4550","IBB","SG9999015952.SGD","SG9999015978.USD","ASMB","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154623157","title":"Assembly Biosciences旗下Gs-1179預計2026年底前將推進至生殖器皰疹二期臨床試驗階段","url":"https://stock-news.laohu8.com/highlight/detail?id=1154623157","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1154623157?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 04:02","pubTimestamp":1788897731,"startTime":"0","endTime":"0","summary":"Assembly Biosciences公司日前宣布，其研发管线中的候选药物Gs-1179有望在2026年年底之前顺利迈入针对生殖器疱疹的二期临床试验阶段。生殖器疱疹作为一种常见的性传播感染疾病，全球患者群体庞大，对创新疗法的需求十分迫切。Assembly Biosciences正积极加速该药物的研发进程，以期尽早为患者带来新的治疗选择。业内分析人士指出，若Gs-1179能够顺利通过后续试验的严格考验，将可能重塑该适应症的市场格局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z3581.USD","LU0965509101.SGD","LU0234570918.USD","LU0823416689.USD","LU2468319806.SGD","ASMB","BK4532","LU1066053197.SGD","BK4568","LU0289739699.SGD","LU0859254822.USD","SG9999015952.SGD","LU1934455194.USD","LU0889565916.HKD","LU1037948541.HKD","LU0965508806.USD","TMED","LU1057294990.SGD","LU0965509283.SGD","LU1934455863.HKD","LU2089984988.USD","SG9999015945.SGD","LU1674673428.USD","LU0114720955.EUR","BIB","LU1778281490.HKD","BK4588","IE00B7SZLL34.SGD","BK4550","LU2087621335.USD","IE00BZ1G4Q59.USD","LU2112291526.USD","LU1674673691.USD","LU1061106388.HKD","BK4566","IE00B19Z3B42.SGD","LU0320765992.SGD","LU1934455277.USD","LU0058720904.USD","LU1571399168.USD","LU0861579265.USD","LU1585245621.USD","IE00B3T34201.USD","IBB","IE00BSNM7G36.USD","MEDI","LU2324357040.USD","BK4578","SG9999015978.USD","IBBQ","LU0965509010.AUD","BBH","TBXU","IE00BKVL7J92.USD","LU0882574055.USD","LU1430594728.SGD","BK4139","LU1023059063.AUD","LU1839511570.USD","BMED","LU0109394709.USD","LU0122379950.USD","IE0002270589.USD","SG9999015986.USD","BK4583","GILD","BK4585","LU1066051498.USD","LU2357627491.SGD","LU1037948897.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115029168","title":"Assembly Biosciences：吉利德獨享HSV HPI項目臨床開發與商業化權利","url":"https://stock-news.laohu8.com/highlight/detail?id=1115029168","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1115029168?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 04:01","pubTimestamp":1788897702,"startTime":"0","endTime":"0","summary":"Assembly Biosciences宣布，吉利德科学已保留其HSV HPI项目的独家临床开发及商业化权利。这一决定标志着双方合作进一步深化，吉利德将全权主导该项目的后续推进与市场布局。对于Assembly Biosciences而言，此举不仅明确了合作伙伴的战略优先级，也为其自身聚焦其他管线资源提供了更大灵活性。业内观察人士指出，HSV HPI项目的独家授权，反映了吉利德在抗病毒治疗领域持续加码的雄心，同时也凸显了该类创新疗法在未被满足的医疗需求中所蕴含的巨大潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0114720955.EUR","SG9999015945.SGD","LU0289739699.SGD","LU1061106388.HKD","TBXU","MEDI","IE00BKVL7J92.USD","IE00BSNM7G36.USD","LU1934455277.USD","IE00B19Z3581.USD","LU0889565916.HKD","LU0965509283.SGD","LU0859254822.USD","LU1571399168.USD","LU1674673428.USD","LU2089984988.USD","LU0122379950.USD","LU2468319806.SGD","LU0965509010.AUD","BK4578","LU1057294990.SGD","LU1430594728.SGD","LU1066053197.SGD","GILD","LU1585245621.USD","BIB","BK4550","BK4532","BMED","LU1778281490.HKD","LU0234570918.USD","LU1066051498.USD","LU1023059063.AUD","LU0965508806.USD","BK4568","BK4588","LU1674673691.USD","IE00B7SZLL34.SGD","IE00B3T34201.USD","LU0882574055.USD","LU1037948541.HKD","IBBQ","LU0965509101.SGD","LU0058720904.USD","BBH","SG9999015986.USD","ASMB","IBB","IE00B19Z3B42.SGD","IE0002270589.USD","LU0109394709.USD","LU0823416689.USD","BK4139","LU2357627491.SGD","LU0320765992.SGD","IE00BZ1G4Q59.USD","SG9999015978.USD","TMED","LU1037948897.HKD","LU1934455863.HKD","SG9999015952.SGD","BK4583","LU2324357040.USD","BK4566","LU1839511570.USD","LU0861579265.USD","LU1934455194.USD","BK4585","LU2112291526.USD","LU2087621335.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179230759","title":"Assembly Biosciences行使與吉利德關於HSV解旋酶-引物酶抑制劑項目的美國利潤分成選擇權","url":"https://stock-news.laohu8.com/highlight/detail?id=1179230759","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1179230759?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 04:01","pubTimestamp":1788897669,"startTime":"0","endTime":"0","summary":"Assembly Biosciences公司已正式行使与吉利德科学就HSV解旋酶-引物酶抑制剂项目达成的美国利润分成选择权。这一战略举措标志着双方合作进入新阶段，有望加速该抗病毒疗法的临床开发与商业化进程。通过行使该选择权，Assembly Biosciences将能够分享该药物在美国市场的未来收益，同时借助吉利德在抗病毒领域的深厚积累与市场渠道，共同推进这一潜在重磅药物的落地。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z3581.USD","LU1934455863.HKD","BK4566","BK4578","LU1066053197.SGD","LU1585245621.USD","IE00B3T34201.USD","IE00B19Z3B42.SGD","LU0122379950.USD","LU0320765992.SGD","BK4550","LU1674673691.USD","LU0861579265.USD","LU0882574055.USD","BK4532","IE00BSNM7G36.USD","LU1037948541.HKD","LU1037948897.HKD","LU1061106388.HKD","LU0114720955.EUR","BK4588","LU1430594728.SGD","TMED","LU2324357040.USD","SG9999015945.SGD","SG9999015986.USD","LU2357627491.SGD","IBBQ","LU0289739699.SGD","BIB","LU0058720904.USD","LU0109394709.USD","MEDI","ASMB","LU0965508806.USD","LU2112291526.USD","SG9999015952.SGD","BK4139","IE0002270589.USD","BK4568","SG9999015978.USD","BK4583","IE00BZ1G4Q59.USD","LU1778281490.HKD","IE00BKVL7J92.USD","LU0965509283.SGD","LU1934455194.USD","LU2087621335.USD","LU2089984988.USD","LU2468319806.SGD","LU1066051498.USD","IBB","LU0823416689.USD","LU1057294990.SGD","LU0965509101.SGD","BBH","LU1674673428.USD","IE00B7SZLL34.SGD","BK4585","LU0859254822.USD","LU1571399168.USD","LU1934455277.USD","LU0889565916.HKD","BMED","LU0234570918.USD","TBXU","GILD","LU0965509010.AUD","LU1839511570.USD","LU1023059063.AUD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666374570","title":"吉利德科學(GILD)股票9月8日盤中下跌3.26%：釋放什麼信號？","url":"https://stock-news.laohu8.com/highlight/detail?id=2666374570","media":"TradingKey中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666374570?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 01:16","pubTimestamp":1788887780,"startTime":"0","endTime":"0","summary":"• 吉利德在经历了长达数月的持续上涨后，因获利回吐而出现回调。\n• 强劲的第二季度营收主要受其旗舰 HIV 和 Trodelvy 产品线的推动。\n• 分析师维持“买入”评级，平均目标价为 157.79 美元。","market":"other","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/zh-hans/news/market-movers/262156554-market-movers-gild-20260908","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765992.SGD","LU0058720904.USD","IE00BKVL7J92.USD","LU0965509101.SGD","LU2324357040.USD","LU0114720955.EUR","IBB","LU0289739699.SGD","TBXU","IBBQ","BBH","IE00BSNM7G36.USD","LU1839511570.USD","BK4578","LU1674673691.USD","LU1674673428.USD","LU0823416689.USD","LU1571399168.USD","SG9999015952.SGD","IE00B7SZLL34.SGD","MEDI","IE00BZ1G4Q59.USD","SG9999015945.SGD","BMED","GILD","IE0002270589.USD","LU1778281490.HKD","LU1934455277.USD","LU2112291526.USD","IE00B3T34201.USD","TMED","BK4583","IE00B19Z3581.USD","LU0109394709.USD","LU2087621335.USD","LU1430594728.SGD","BIB","LU0122379950.USD","BK4568","LU0861579265.USD","LU1023059063.AUD","LU1037948541.HKD","BK4585","SG9999015978.USD","SG9999015986.USD","LU0965508806.USD","BK4532","IE00B19Z3B42.SGD","LU0859254822.USD","LU0882574055.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":2,"totalSize":63,"code":"91000000","status":"200"}]}}